Navigation Links
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Date:6/12/2008

al generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). Between 30 to 40% of US adults report some level of insomnia and insomnia is a chronic problem for about 10% of the US adult population. The lack of restful sleep may impair the person's ability to carry out their daily responsibilities because they are too tired or have trouble concentrating.

Insomnia has a variety of causes. It is often a symptom of some other disease or condition (e.g. life stress, psychiatric and medical disorders, or use of certain medications), but it can also be a distinct disorder. The prevalence of insomnia increases with age and is more common in women. Common symptoms of acute insomnia are sleepiness, negative mood and impairment of performance. Chronic insomnia is often associated with fatigue, mood changes, difficulty concentrating and impaired daytime functioning.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Mer
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
4. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
5. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  St. Vincent Healthcare is ... care. Already following strict disinfection routines, St. Vincent ... to eliminate harmful germs, like Ebola, methicillin-resistant ... that can infect patients during their hospital stay. ... Logo - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
(Date:4/21/2015)... , April 21, 2015   iRhythm Technologies, ... the advancement of cardiac care, announced today that Banner ... in the U.S., will now be offering iRhythm,s ZIO ... continuous cardiac monitoring. "At Banner Health, we ... patient outcomes and services," said John Hensing , ...
(Date:4/21/2015)... 21, 2015 Workers, compensation pharmacy spending increased ... in utilization helped offset a 7 percent increase in ... today by Express Scripts (NASDAQ: ESRX ). ... Trend Report discusses the overall pharmacy trend as well ... Opioid Management Mitigates Spend Increases ...
Breaking Medicine Technology:St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 2Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4
... 10, 2011 ThermoGenesis Corp. (Nasdaq: KOOL ... that process and store adult stem cells, said today ... Biotechnology Co., Ltd ("Beike"), a leading stem cell and ... agreement, ThermoGenesis will supply Beike with an initial stocking ...
... The Consumer Healthcare Products Association (CHPA) is pleased to ... Act, introduced today by Senator Kay Bailey Hutchison (R-Tex.) ... repeal a requirement enacted into law as part of ... that requires consumers to obtain a prescription in order ...
Cached Medicine Technology:ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company 2ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company 3ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company 4CHPA Applauds Introduction of The Patients' Freedom to Choose Act 2
(Date:4/21/2015)... Carinsurancehints.com has released a new blog post presenting ... auto insurance prices . , Commuting on ... should review their insurance options before deciding what plan ... forms. Some of the popular policies provide liability, collision ... rates and find the best prices in their area ...
(Date:4/21/2015)... 21, 2015 Edward Avalos, USDA Under ... Kawamura, former Secretary of the California Department of Food ... the 2nd Annual GrowRIVERSIDE Conference: The Future of Local ... inclusion of these nationally known experts intensifies an already ... farmers and others slated to speak at the June ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Respected ... PACS® strategy , Visage Imaging Inc. (“Visage”), ... PME), has signed a seven-year contract with University ... in Northern Florida. The deal furthers the penetration ... hospital space, a key area of the North American ...
(Date:4/21/2015)... 2015 Wojo Nutrition announces ... innovation at its healthiest, will carry Wojo Nutrition's lines ... At Wojo Nutrition, they’ve launched a revolution in the ... tailored to meet their multifaceted goals. Their line of ... any beverage, has been specially formulated to be as ...
(Date:4/21/2015)... Now in its fifteenth year, the TU-Automotive Detroit ... 3,000 senior attendees from across the automotive, technology ... on June 3 and 4. This year leading ... are set to deliver headline and keynote presentations ... as connectivity paves the way towards smart mobility ...
Breaking Medicine News(10 mins):Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 3
... the $50 million “YES Medical Technology Fund”, a ... companies with revenues and profits to expand their ... will provide growth capital to medtech companies that ... profitable (minimum $2 million EBITDA), and have the ...
... Unilens Vision Inc. (OTC,Bulletin Board: UVICF; TSX Venture Exchange: ... lenses, today reported,its operating results for the first quarter ... Net sales, excluding royalty income, increased ... in the previous year first,quarter (FY2008). The increase ...
... NEW YORK, Nov. 21 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... 17, 2008, it received notice from The Nasdaq Stock ... in compliance with Marketplace Rule 4310(c)(3), which requires the ... equity, or $35,000,000 market value of listed securities, or ...
... DETROIT, Nov. 21 Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext US: ... the FDA warning letter on November 24, 2008 as planned.,In ... requested a,response from Caraco within 15 business days, ending November ... previously disclosed, the warning letter was issued as a follow ...
... VTAL ), a leading provider of advanced visualization ... agreed to,renew their global distribution agreement for five years, ... As under the previous agreement, Toshiba will offer ... than 50 nations in North and,South America, Europe, the ...
... surgery but either couldn,t afford it or were afraid of undergoing ... cosmetic surgery with a nonsurgical facelift that,s extremely safe, minimally invasive, ... ask for? , ... Coral Gables, FL (PRWEB) November ...
Cached Medicine News:Health News: Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies 2Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 4Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 2Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter 2Health News:Vital Images and Toshiba Renew Distribution Agreement 2Health News:Vital Images and Toshiba Renew Distribution Agreement 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 2Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 4
... The Fundus 20mm is a ... Lens. The Fundus 20mm provides ... increased 20mm contact element. The ... the contact element sits under ...
... The Volk Area Centralis® is excellent ... neovascularization and changes from macular degeneration, ... proliferative diabetic retinopathy and other retinal ... laser treatment of these conditions providing ...
... delivers the widest field of view ... .5x image magnification provides simultaneous visualization of ... providing a greater margin of safety during ... the ideal lens for visualization and treatment ...
... it the "Super 90". Volk's SuperField® has ... diagnosis for today's discriminating practitioner. Its ideal ... make it perfect as the primary high ... SuperField has been specifically designed for increased ...
Medicine Products: